RxDoctor Payments Data

Warren Hayes, MD

Family Medicine · Red Oak, IANPI 1932215274

Payments from drug & device makers

$1,343in general payments, 2019–2025

Across 99 payments — averaging $13.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$319
  • Pfizer$256
  • AbbVie$173
  • Boehringer Ingelheim$103
  • AstraZeneca$97
  • Sanofi-aventis U.S. LLC$94
  • plus $300 from 10 others

What the payments were for

  • Food & beverage$1,343100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,343 in reported general payments places this provider in the 85th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$3,089
Medicare patients
30
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban259$174,318
OzempicSemaglutide100$104,133
JardianceEmpagliflozin65$61,853
Tresiba Flextouch U-200Insulin Degludec59$50,003
XareltoRivaroxaban32$40,284
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog111$40,227
TrulicityDulaglutide49$39,031
MyrbetriqMirabegron39$24,047
FarxigaDapagliflozin Propanediol22$18,320
Breo ElliptaFluticasone/Vilanterol43$18,278
EntrestoSacubitril/Valsartan14$14,111
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$13,637
Spiriva HandihalerTiotropium Bromide23$12,534
Fiasp FlextouchInsulin Aspart (Niacinamide)21$8,048
Lantus SolostarInsulin Glargine,hum.Rec.Anlog71$7,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$256$174,318259 claims
Novo NordiskOzempic$319$104,133100 claims
Boehringer IngelheimJardiance, Combivent Respimat$103$69,14980 claims
Johnson & JohnsonXarelto$48$40,28432 claims
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta$28$34,19767 claims
Astellas Pharma US IncMyrbetriq$87$24,04739 claims
AstraZenecaFarxiga, Symbicort$97$23,88845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Red Oak

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →